Fezolamine (Win-41,528-2) is a drug which was investigated by Sterling Drug as an antidepressant in the 1980s.[1][2] The isomeric N,N-dimethyl-4,5-diphenyl-1H-pyrazole-1-propanamine was completely inactive in the primary antidepressant screens.

Clinical data
Routes of
ATC code
  • none
Legal status
Legal status
  • In general: uncontrolled
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
Molar mass305.42 g/mol g·mol−1
3D model (JSmol)

It acts as a serotonin, norepinephrine, and dopamine reuptake inhibitor, with 3- to 4-fold preference for the former neurotransmitter.[3] It was found to be effective and well tolerated in clinical trials but was never marketed.[4]

See also


  1. U.S. Patent 4,182,895
  2. Bailey, D. M.; Hansen, P. E.; Hlavac, A. G.; Baizman, E. R.; Pearl, J.; Defelice, A. F.; Feigenson, M. E. (1985). "3,4-Diphenyl-1H-pyrazole-1-propanamine antidepressants". Journal of Medicinal Chemistry. 28 (2): 256–60. doi:10.1021/jm00380a020. PMID 3968690.
  3. Baizman, E. R.; Ezrin, A. M.; Ferrari, R. A.; Luttinger, D (1987). "Pharmacologic profile of fezolamine fumarate: A nontricyclic antidepressant in animal models". The Journal of Pharmacology and Experimental Therapeutics. 243 (1): 40–54. PMID 3668867.
  4. Zisook, S.; Mendels, J.; Janowsky, D.; Feighner, J.; Lee, J. C. M.; Fritz, A. (1987). "Efficacy and Safety of Fezolamine in Depressed Patients". Neuropsychobiology. 17 (3): 133–8. doi:10.1159/000118353. PMID 3683802.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.